Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

On March 13, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed a five-year patent term extension (“PTE”) for ...

Spring House, Pennsylvania Wednesday, March 19, 2025, 14:00 Hrs [IST] ...

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...

I have no problem with my family consuming Red 3,' said Joseph Borzelleca, professor emeritus of pharmacology and toxicology ...

This is the third part of a series on the illegalities of a new community forest in Grand Bassa County. VAMBO, Grand Bassa County – Early last month, The DayLight started a series on a newly ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Joseph Borzelleca published a study on the food coloring Red No. 3. The FDA cited his work when banning the additive in ...